RavenQuest Partner McGill University Secures Cannabis License
26 9월 2019 - 7:00PM
RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt:
1IT) (the “
Company” or
“
RavenQuest”), one of Canada’s most innovative
cannabis producers, is pleased to announce that its research
partner, McGill University, has received a license from Health
Canada which allows for the possession and production of cannabis
for research purposes.
The license allows RavenQuest and McGill to
continue important research around the cannabis plant. The
research continues to focus on cultivar recognition, plant
stabilization, yield maximization and disease resistance of the
cannabis plant.
RavenQuest CEO, George Robinson, commented that
“throughout our partnership with McGill, research has thus far
uncovered several key beneficial microbes which have shown
significant potential to improve yield and disease
resistance. The Health Canada license will allow RavenQuest
and McGill to confirm our findings by applying the microbes
directly to the cannabis plant.”
“RavenQuest’s foundation is grounded in science
and innovation. As a company, we have always maintained that large
scale Cannabis producers need to develop non-GMO methods to produce
genetically consistent, disease resistant and biologically stable
plant material that will meet pharmaceutical standards for
clinicians to conduct medical research trials. With the
granting of this license, the research we are conducting with our
partners at McGill moves us even closer toward that end,” Robinson
continued.
For more information, access RavenQuest’s
investor presentation, fact sheet and videos here.
Follow RavenQuest:
Twitter:https://twitter.com/RQBGlobal
Instagram: https://www.instagram.com/ravenquestbm/
Facebook:https://www.facebook.com/RavenQuest-BioMed-2355335751374131/?view_public_for=2355335751374131
LinkedIn:https://www.linkedin.com/company/ravenquest-biomed
About RavenQuest BioMed
Inc.
RavenQuest BioMed Inc. is a diversified publicly
traded cannabis company with divisions focused upon cannabis
production, management services & consulting and specialized
research & development. RavenQuest is a licensed producer with
facilities located in Markham, Ontario and Edmonton, Alberta.
RavenQuest maintains a research partnership with
McGill University focused upon cultivar (strain) recognition, plant
stabilization and yield maximization of the cannabis plant.
The Company focuses on partnerships with Indigenous
communities.
On Behalf of the Board of Directors
ofRAVENQUEST BIOMED INC.
“George Robinson”Chief Executive Officer
For further information, please contact: Mathieu
McDonald, Corporate Communications1-877-282-1586
Neither the Canadian Securities Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Canadian Securities Exchange) accepts
responsibility for the adequacy or accuracy of this press release,
which has been prepared by management.
Cautionary Note Regarding Forward-Looking
Statements
All statements in this press release, other than
statements of historical fact, are "forward-looking information"
with respect to the Company within the meaning of applicable
securities laws. Examples of such statements include statements
with respect to the construction of cannabis facilities in Europe
and the cannabis production capacity and location of such
facilities, the name of the joint venture and the funding of the
Joint Venture by the Company’s Joint Venture partner (which is
under no obligation to provide funding). The Company provides
forward-looking statements for the purpose of conveying information
about current expectations and plans relating to the future and
readers are cautioned that such statements may not be appropriate
for other purposes. By its nature, this information is subject to
inherent risks and uncertainties that may be general or specific
and which give rise to the possibility that expectations,
forecasts, predictions, projections or conclusions will not prove
to be accurate, that assumptions may not be correct and that
objectives, strategic goals and priorities will not be achieved.
These risks and uncertainties include but are not limited those
identified and reported in the Company’s public filings under the
Company’s SEDAR profile at www.sedar.com. Although the Company has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking information, there may be other
factors that cause actions, events or results not to be as
anticipated, estimated or intended. There can be no assurance that
such information will prove to be accurate as actual results and
future events could differ materially from those anticipated in
such statements. The Company disclaims any intention or obligation
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise unless
required by law.
RavenQuest BioMed (CSE:RQB)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
RavenQuest BioMed (CSE:RQB)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024